2025-08-20 - Analysis Report
Okay, here's the analysis of Merck & Co Inc (MRK) based on the provided data, formatted for a concise English report:

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and manufactures a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -8.23%
*   **VOO Cumulative Return:** 100.85%
*   **Absolute Divergence:** -95.0 (MRK is lagging significantly behind the S&P 500)
*   **Relative Divergence:** 0.1 (The current divergence is near its historical minimum within the observed range).

**Analysis of Alpha, Beta:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 5.0%    | 58.2%   | -24.0%  | -0.0  | 135.2  |
| 2016-2018  | 43.0%   | 66.4%   | 25.0%   | -0.1  | 183.7  |
| 2017-2019  | 40.0%   | 66.4%   | 11.0%   | 0.3   | 218.6  |
| 2018-2020  | 20.0%   | 66.4%   | 0.0%    | 0.3   | 196.6  |
| 2019-2021  | -1.0%   | 65.6%   | -50.0%  | 0.3   | 193.0  |
| 2020-2022  | 13.0%   | 69.5%   | 11.0%   | 0.3   | 279.5  |
| 2021-2023  | 31.0%   | 69.5%   | 13.0%   | 0.3   | 274.6  |
| 2022-2024  | -7.0%   | 69.5%   | -33.0%  | 0.2   | 250.6  |
| 2023-2025  | -60.0%  | 61.4%   | -113.0% | 0.4   | 212.1  |

*   **CAGR Trend:** The CAGR (Compound Annual Growth Rate) shows significant volatility, with substantial growth periods followed by sharp declines, particularly in the most recent period (2023-2025).
*   **MDD:** The Maximum Drawdown (MDD) remains consistently high, indicating significant risk exposure over the analyzed periods.
*   **Alpha:** Alpha values are highly variable, with recent periods showing negative values, indicating underperformance relative to the benchmark.
*   **Beta:** Beta values are relatively stable, generally between 0.2 and 0.4, suggesting moderate market correlation.
*   **Capitalization:** Market capitalization has fluctuated, reaching a peak and then declining recently.

### 2. Recent Stock Price Movement

*   **Current Price:** 84.22
*   **Last Market Data:**
    *   **Price:** 84.93
    *   **Previous Close:** 84.22
    *   **Change:** 0.84 (Price increase compared to previous close)
*   **5-Day Moving Average:** 82.84
*   **20-Day Moving Average:** 81.78
*   **60-Day Moving Average:** 80.54

The current price is above all three moving averages, suggesting a short-term upward trend. The recent price increase may indicate a positive reaction to recent news or events.

### 3. Indicators Analysis

*   **Market Risk Indicator (MRI):** 0.329 (Low Risk)
*   **RSI:** 55.43 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.44 (Positive but relatively low, suggesting limited momentum)
*   **Hybrid Signal:** "cash_0%_Buy 90% of cash (17 shares - Safe - MRI:0.33)" - A strong buy signal, suggesting the system recommends investing a significant portion of cash reserves.
*   **Recent (20-day) Relative Divergence Change:** -0.6 (Short-term decline in relative performance)
*   **Expected Return:** 223.1% (High potential for long-term outperformance vs. S&P 500 if investing today)

The low MRI score and the buy signal suggest a favorable buying opportunity, despite the short-term negative divergence trend. The high expected return further supports a long-term investment perspective. The price change of 0.84 might indicate some upward momentum, but it is important to see if this trend continues.

### 4. Recent News & Events

*   **2025-08-18:** Major business developments, regulatory changes, or market events.
*   **2025-08-20:** Analysts discussing recent performance and outlook.
*   **2025-08-17:** Notable stock volatility.
*   **2025-08-19:** Market experts highlighting risks and opportunities, urging monitoring of news and announcements.

These news snippets indicate that Merck is experiencing significant activity, warranting close monitoring of company announcements and market reactions. The stock's volatility suggests that investors should be prepared for potential price swings.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-08-05 | 1.76 | 15.81 B$  |
| 2025-05-02 | 2.01 | 15.53 B$  |
| 2024-11-06 | 1.25 | 16.66 B$  |
| 2024-08-05 | 2.15 | 16.11 B$  |
| 2025-08-05 | 2.15 | 16.11 B$  |

*   **Trend:** The data shows fluctuating EPS and Revenue. Monitoring these figures over a longer period is important to determine a clear trend.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE   |
|------------|-----------|-------|
| 2025-06-30 | $48.99B   | 9.04% |
| 2025-03-31 | $48.34B   | 10.51%|
| 2024-12-31 | $46.31B   | 8.08% |
| 2024-09-30 | $44.50B   | 7.09% |
| 2024-06-30 | $43.58B   | 12.52%|

*   **Trend:** Revenue and Profit Margin show relative stability with some fluctuations. Equity and ROE also exhibit some variance.

### 7. Overall Assessment

Merck & Co Inc (MRK) is currently underperforming compared to the S&P 500, but recent price action shows some positive momentum. The low MRI and buy signal are encouraging. The high expected return suggests potential long-term upside. However, the stock's volatility and recent negative divergence trends warrant caution. Investors should closely monitor company news and financial performance to make informed decisions. The recent business developments, regulatory changes, and analyst discussions indicate the importance of staying informed about Merck's future.
